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Comparison of the acute ocular
manifestations of Stevens-Johnson
syndrome and toxic epidermal necrolysis in
Chinese eyes: a 15-year retrospective study
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Abstract
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening
conditions that initially affect the skin and mucous membranes. The aim of this study was to compare the acute
ocular manifestations between SJS and TEN.
Methods: The initial presenting ophthalmic records of patients with either SJS (<30% body surface area involvement)
or TEN (> = 30% involvement), who were treated at one tertiary burn center in Hong Kong between 1999 and 2014,
were retrospectively analyzed and compared.
Results: A total of 20 SJS and 12 TEN cases were included. All were drug-induced. The patient demographics and
treatment received were comparable. Overall, 40% of SJS and 75% of TEN patients had acute ocular surface inflammation.
When comparing the two groups, there was a significant difference in the number of cases with mild involvement (5% in
SJS, 42% in TEN, p= 0.01), while no statistically significant differences were found (p > 0.05) comparing between the
moderate (15% in SJS, 0% in TEN) and severe groups (20% in SJS, 33% in TEN).
Conclusions: Ocular surface inflammation was common during the acute phase in both SJS and TEN. TEN had a significantly
higher number of cases with mild ocular involvement when compared with SJS, but no significant difference
between the number of moderate and severe cases between the two groups.
Keywords: Ocular surface disease, Severe cutaneous adverse reactions, Stevens-Johnson syndrome, Toxic epidermal
necrolysis, Asians
Background
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are acute exfoliating diseases of the
skin and mucosa and represent different ends of the
spectrum of the same clinical entity of severe cutaneous
adverse reactions. Since 1993 they have been differenti-
ated by total body surface area (BSA) of involvement,
with SJS representing the mild end of the spectrum
(<10% BSA involvement), TEN forming the most exten-
sive form of the disease (> = 30% involvement) and SJS/
TEN overlap in cases with 10 to 30% involvement [1–3].
SJS and TEN are characterized histologically by wide-
spread keratinocyte death and epidermal necrosis result-
ing in splitting of sub-epidermal layers, resulting
clinically in tissue loss of the skin and mucous mem-
branes [4]. Although rare, the conditions result in sig-
nificant morbidity and mortality [5].
Ophthalmic involvement is common in patients with
SJS and TEN, and the acute ocular involvement is re-
ported to occur in 50 to 88% of cases [6, 7]. For affected
patients, acute ocular surface inflammation results in
devastating long-term sequelae, including dry eye dis-
ease, recurrent or persistent corneal epithelial defects,
conjunctival scarring, symblephera formation, cornea
limbal stem cell deficiency and corneal scarring [6, 8–12].
Currently, the evidence on whether the extent of ocular
* Correspondence: nlk008@hku.hk
2Department of Ophthalmology, The University of Hong Kong, Room 301,
Level 3, Block B, Cyberport 4, 100 Cyberport Road, Pok Fu Lam, Hong Kong
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chow et al. BMC Ophthalmology  (2017) 17:65 
DOI 10.1186/s12886-017-0464-9
involvement is the same between SJS and TEN, or worse
in either one of the entities, is still conflicting [6, 13–15].
One recent study reported that the SCORTEN value,
which is a severity-of-illness score for SJS and TEN that
predicts overall mortality, did not correlate with the sever-
ity of eye involvement in the acute setting [7]. The aim of
this study is to compare the acute ocular surface manifes-
tations of SJS and TEN among in-patients at a tertiary
burn care center in Hong Kong over a 15-years period.
Methods
This is a retrospective cross-sectional study using initial
presenting case records of all consecutive patients, who
were admitted as inpatients with a diagnosis of either
SJS or TEN between the 1st of January 1999 and the
31st of December 2014 at the Queen Mary Hospital,
Hong Kong. The study was conducted in accordance
with the tenets of the Declaration of Helsinki and was
approved by the Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong
West Cluster. Diagnosis was made by dermatologists
based on clinical history or skin biopsy results and pa-
tients were classified by the criteria outlined by Bastuji-
Garin et al. [1] In our center, patients with less than 30%
BSA involvement were all grouped as SJS or SJS/TEN
overlap and those with 30% or more BSA involvement
as TEN. Patients without available ophthalmic assess-
ment records were excluded from analysis.
Patient data, including demographics, ocular slit lamp
examination findings and specific treatment received,
were extracted from patient records. Most studies con-
sidered the acute stage of the disease as the time of on-
set of the skin changes [3, 6]. In this study, the acute
phase referred to the time period when the patient was
admitted to the burn intensive care unit, which closely
followed the onset of skin changes. The primary out-
come measure was severity of acute phase ophthalmic
involvement, which was classified into mild, moderate
and severe using clinical parameters on ocular slit lamp
examination described by Power et al. [7, 15, 16] Mild
ocular involvement comprises any or all of the following:
eyelid edema, eyelid skin involvement including denuda-
tion and desquamation, mild corneal involvement (punc-
tate fluorescein staining), mild conjunctival injection,
mucous discharge, or chemosis. Moderate involvement
comprises membranous conjunctivitis, epithelial defects
with more than 30% healing with medical treatment,
corneal ulceration, or corneal infiltrates. Severe involve-
ment comprises acquired eyelid malpositions, symble-
pharon formation, non-healing corneal epithelial defects,
visual loss or conjunctival fornix foreshortening. We
have also classified the severity using another more re-
cent grading system proposed by Sotozono et al. [17]
This acute ocular severity scoring system mainly focused
on the ocular surface inflammation and epithelial necro-
sis or apoptosis. Using this system, Grade 1 included
eyes with conjunctival hyperemia, which indicated ocular
surface inflammation, Grade 2 included eyes with
pseudo-membrane formation or presence of epithelial
defects, and Grade 3 included eyes with both pseudo-
membrane formation and epithelial defects. Secondary
outcome measures include the culprit agent and any
specific systemic or local treatment received (other
than the supportive treatment), including the use of
intravenous immunoglobulin or amniotic membrane
transplantation.
Statistical analyses were performed using IBM/SPSS
software version 21 (IBM/SPSS Inc., Chicago, IL, USA).
Descriptive statistics were reported. Patients were
divided into the “SJS or SJS/TEN overlap” group when
BSA involvement was less than 30%, and “TEN” group
with 30% or greater BSA involvement. The more severe
eye was chosen for comparison in case of asymmetrical
involvement. If a patient was assessed multiple times
during the acute phase, the most severe assessment was
used for analysis. Comparisons were performed with the
chi-square test or Fisher's exact test for categorical data
and independent t-test for continuous data. A p-value of
< 0.05 were regarded as statistically significant.
Results
During the 15-years study period, a total of 56 in-
patients were diagnosed with SJS or SJS/TEN overlap
(39 cases) or TEN (17 case). 24 patients (19 SJS or SJS/
TEN overlap and 5 TEN) were excluded due to the lack
of available ophthalmic assessment charts. The main rea-
son was that the initial ocular assessment was performed
in the primary referring center, and no further ophthal-
mic consultations were made after transferring to our
center as there was no evidence of ocular involvement.
After exclusion, a total of 32 patients were included for
the analysis (Table 1). 20 were SJS or SJS/TEN overlap
and 12 were TEN patients. The mean age was 44.8 ± 25.0
Table 1 This table shows the demographics and specific ocular
or systemic treatment received during the acute phase of the
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN). All these were comparable between the two groups
Stevens-Johnson
Syndrome and
SJS/TEN overlap
(n = 20)
Toxic Epidermal
Necrolysis
(n = 12)
p - value
Age 44.8 ± 25.0 44.3 ± 26.7 0.960
Sex (Male: Female ratio) 10: 10 3: 9 0.267
Intravenous Pulse Steroid 20 (100%) 12 (100%) 1.000
Amniotic Membrane
Transplant
1 (5%) 1 (8.33%) 1.000
Intravenous immunoglobulin 11 (55%) 6 (50%) 0.784
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(range 15–59 years old) for the SJS or SJS/TEN overlap
group and 44.3 ± 26.7 (range 3–89 years old) for the TEN
group (p = 0.96). The male: female ratio was 10:10 and 3:9
respectively (p = 0.267). All patients were Chinese, and all
cases of SJS or TEN were drug-induced. However, the cul-
prit drug could not be identified in some of the cases, as
these patients were given a number of new drugs (several
antibiotics, for example) at the same time prior to the dis-
ease onset. The visual acuity could not be documented in
almost all cases as patients were routinely sedated for pain
control in our burn unit during the acute phase of illness.
The acute ocular manifestations of SJS or SJS/TEN over-
lap and TEN patients were classified as mild, moderate
and severe ocular involvement using the classification sys-
tem described in the methodology. Overall, the ocular
involvement during the acute phase 53% (17 out of 32 pa-
tients) in our series, with 40% (8 patients) in the SJS or
SJS/TEN overlap group and 75% (9 patients) in the TEN
group. Table 2 summarized the findings. For SJS or SJS/
TEN overlap patients, 1 (5%) had mild ocular involve-
ment, 3 (15%) had moderate involvement and 4 (20%) had
severe involvement. In comparison, for TEN patients, 5
(42%) had mild involvement, 0 (0%) had moderate in-
volvement and 4 (33%) had severe involvement. The
TEN group had significantly more mild involvement
than the SJS or SJS/TEN overlap group (p = 0.01),
while in all other groups, no statistically significant
differences were found (p > 0.05).
We have also graded our series using the system de-
scribed by Sotozono et al, which graded the cases from
grade one to three as shown in Table 3 [17]. For our SJS
or SJS/TEN overlap patients, the distribution of grade 1
to 3 was 5% (1 case), 20% (4 cases) and 15% (3 cases)
respectively, whereas that for TEN was 42% (5 cases), 17%
(2 cases) and 17% (2 cases). Again, the TEN group had sig-
nificantly more mild involvement than the SJS or SJS/TEN
overlap group (p = 0.018), while in all other groups, no sta-
tistically significant differences were found (p > 0.05).
For treatment, majority of patients received conven-
tional local therapy, which consisted of frequent topical
artificial tears, topical steroids and topical antibiotics.
Glass rodding was performed for any signs of early ocu-
lar surface adhesions. Systemically, all cases were rou-
tinely given early intravenous steroids (1 mg/kg/day for
3 days). In addition, 1 SJS (5%) patient and 1 TEN
(8.3%) patient underwent amniotic membrane trans-
plantation (AMT) 5 days after admission (p = 1.0). For
systemic therapy, other than supportive treatment, 11
SJS or SJS/TEN overlap (55%) and 6 TEN (50%) patients
received intravenous immunoglobulin (IVIG) treatment
within 5 days after admission (p = 0.784). The overall
mortality rate was zero in our series.
Discussion
Ocular surface disease is a common manifestation of SJS
and TEN. We reported an overall 53% acute ocular in-
volvement rate in our series, and this fell into the re-
ported range of 50 to 88% in the literature [6]. Most
studies described SJS and TEN as a whole with no com-
parison between these groups [10, 12, 17–21], with a few
exceptions [7, 14, 15]. Morales et al and Gueudry et al
classified the cases into 3 categories (SJS, SJS/TEN over-
lap and TEN) and made comparisons [7, 14], while some
studies focused on comparing SJS cases (<10% BSA
involvement) with TEN (> = 30% BSA involvement)
[15, 17]. In our study, a significant proportion of cases
(especially those form the earlier years) only had the diag-
nosis of SJS (<30%) or TEN (>30%), without clear docu-
mentation of the exact percentage of the body surface
area involved. Thus, in order to achieve similar
Table 2 This table shows the severity of ocular involvement during
the acute phase in the two groups. The grading system was based
on that described by Power et al. [16] There was a statistical
significant difference between the degree of ocular involvement in
the two groups (0.022). Post-hoc analysis showed that the TEN
group had significantly more mild involvement cases than the SJS
or SJS/TEN overlap group (p= 0.01), while in all other groups, no
statistically significant differences were found (p > 0.05)
Ocular involvement Stevens-Johnson syndrome
and SJS/TEN overlap
Toxic epidermal
necrolysis
None 12 (60%) 3 (25%)
Milda 1 (5%) 5 (42%)
Moderateb 3 (15%) 0 (0%)
Severec 4 (20%) 4 (33%)
aMild involvement: lid edema, eyelid skin involvement including denudation
and desquamation, mild corneal involvement (punctate fluorescein staining),
mild conjunctival injection or chemosis only
bModerate involvement: membranous conjunctivitis, corneal epithelial defects
with more than 30% healing with medical treatment, corneal ulceration or
corneal infiltrates
cSevere involvement: symblepharon formation, acquired eyelid malpositions, non-
healing corneal epithelial defects, visual loss or conjunctival fornix foreshortening
Table 3 This table shows the severity of ocular involvement
during the acute phase in the two groups, using the grading
system based on that described by Sotozono et al. [17] The TEN
group had significantly more mild involvement than the SJS or
SJS/TEN overlap group (p = 0.018), while in all other groups, no
statistically significant differences were found (p > 0.05)
Grading Stevens-Johnson syndrome
and SJS/TEN overlap
Toxic epidermal
necrolysis
0 (None) 12 (60%) 3 (25%)
1 (Mild)a 1 (5%) 5 (42%)
2 (Moderate)b 4 (20%) 2 (17%)
3 (Severe)c 3 (15%) 2 (17%)
aGrade 1 (mild involvement): eyes with conjunctival hyperaemia
bGrade 2 (moderate involvement): eyes with pseudomembrane formation or
presence of epithelial defects
cGrade 3 (severe involvement): eyes with both pseudomembrane formation
and epithelial defects
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categorization to facilitate comparisons between different
study results, we grouped all our cases with <30% surface
area involvement as a single “SJS or SJS/TEN overlap”
group and compared this with the TEN group.
We found a higher proportion of TEN patients with
acute ocular surface inflammation than SJS patients
(75% in TEN vs 40% in SJS or SJS/TEN overlap), but the
difference was not statistically significant. There was also
a slightly higher rate of severe ocular involvement in
TEN patients (33.3%) compared to SJS or SJS/TEN over-
lap patients (20%), but the difference was again statisti-
cally insignificant. Only in the mild involvement group,
the TEN patients had a significantly higher involvement
rate than SJS. This was comparable to the study by Yip
et al who studied 81 out of 117 Asian patients with acute
ocular complications [15]. In their study, TEN patients
also had a slightly higher rate of acute ocular involvement
compared with SJS, but the difference was statistically in-
significant despite adjusting for age and gender. They sug-
gested that the similar mechanisms of apoptosis in the
skin and eye in TEN in contrast to SJS patients could be a
possible reason for this. In contrary, in the study by
Morales et al, they reported a higher prevalence of ocular
involvement in the acute phase when the epidermal de-
tachment involved more than 10% of the total body sur-
face area (SJS/TEN overlap and TEN) [7].
Regarding the disease severity classification system,
both studies described above employed the same classifi-
cation described by Power et al. [16] Morales et al re-
ported mild, moderate and severe acute ocular
manifestations as 44, 20 and 20% of cases respectively,
with no significant difference between the three groups
[7]. Similarly, Yip et al reported mild, moderate and se-
vere acute ocular manifestations as 41, 25 and 4% [15].
We initially also employed this classification system as it
was commonly used. However, as addressed by Morales
et al [7], using this classification in the acute phase had
limitations, as the severe category consisted of cicatricial
changes (eyelid malpositions and forniceal foreshorten-
ing) which only present as chronic manifestations rather
than acute ones.
A more recent study by Sotozono et al proposed an-
other grading system for the acute ocular manifestations
[17]. This acute ocular severity scoring system mainly fo-
cused on the ocular surface inflammation and epithelial
necrosis or apoptosis, which they proposed to be the ini-
tial ocular pathologic processes of SJS/TEN. The cicatri-
cial changes were also omitted in the grading system.
Thus, we have also included this grading system in our
results. In their study, the distribution of grade 1 to 3 in
SJS was 36, 25 and 17% respectively, whereas that in
TEN was 23, 35 and 17% respectively. For our series, the
respective distribution was 5, 20 and 15% in SJS group,
whereas that for TEN was 42, 17 and 17%. Compared to
their results, our SJS or SJS/TEN overlap had less mild
involvement, with similar rates in the moderate and
severe grade. For TEN, in contrary, we reported more
mild involvement cases, but fewer patients with mod-
erate grade. However, as we are grading these cases
retrospectively, this might not have reflected the ac-
tual distribution.
The treatment for both SJS and TEN had been evolv-
ing in the past 16 years. There has been increasing use
of early amniotic membrane transplantation (AMT) to
treat severe ocular manifestations as several large case
series have shown improved ocular outcomes as well as
ocular surface histology (Table 4) [19–30]. In the most
recent prospective case series published by Gregory, he
proposed another acute phase grading system to guide
when AMT is indicated [29]. In his study, severe cases
which had either corneal epithelial defect beyond punc-
tate keratopathy, or at least 1 lid margin with staining
involving more than one-third of its length, or any sec-
tion of bulbar or palpebral conjunctiva with staining of
more than 1 cm in largest diameter, should receive ur-
gent AMT to preserve vision and decrease the risk of
ocular surface scarring and dry eyes. For the use of
intravenous immunoglobulin (IVIG), the evidence to
support its use was contradictory [3]. IVIG did not ap-
pear to reduce the severity of visually significant ocular
complications in the study by Yip et al [31], whereas an-
other study by Aihara et al, which combined IVIG with
corticosteroids, showed beneficial effect in reduction of
the severity-of-illness score, as well as improvement in
ophthalmic lesions [18]. Using systemic pulse steroid
alone at disease onset has also been shown to be benefi-
cial in preventing ocular complications [32]. In our
study, all of our cases received early intravenous pulse
steroid (1 mg/kg/day for 3 days). We believe this has sig-
nificantly reduced the severity of the ocular inflamma-
tion in our series, and could explain our lower rate of
amniotic membrane transplantation. However, the bene-
ficial effect of this universal steroid usage was also a
significant confounding factor in this study.
The main limitation of this study was its retrospective
nature. Detailed ocular assessment as suggested by
Sotozono was not available during the earlier years of
the study, and we were only able to group the manifesta-
tions in broad categories [17]. As almost all cases were
assessed at the bedside with portable slip lamp and on
sedated patients, we were unable to report the visual
acuities and the accuracy of the assessment would be
limited by the suboptimal setting. Our sample size was
also relatively small, as we only included cases with a
definite diagnosis of SJS or TEN based on dermatolo-
gist’s assessment and skin biopsy. A high exclusion rate
(24 out of 56 cases, 42.9%) also contributed to our small
sample size. We had a high exclusion rate as these cases
Chow et al. BMC Ophthalmology  (2017) 17:65 Page 4 of 7
Ta
b
le
4
C
as
e
Re
po
rt
s/
St
ud
ie
s
sh
ow
in
g
be
ne
fic
ia
le
ffe
ct
s
of
ea
rly
A
M
T
du
rin
g
th
e
ac
ut
e
ph
as
e
of
TE
N
St
ud
y
Ye
ar
St
ud
y
D
es
ig
n
C
as
es
Se
ve
rit
y
of
O
cu
la
r
D
is
ea
se
A
ge
Ra
ng
e
(Y
ea
rs
ol
d)
Sa
m
pl
e
Si
ze
(P
at
ie
nt
)
Si
gn
ifi
ca
nt
Fi
nd
in
gs
Jo
hn
et
al
[2
2]
20
02
In
te
rv
en
tio
na
l
C
as
e
Re
po
rt
TE
N
Se
ve
re
6
–
8
2
Fi
rs
t
us
e
of
am
ni
ot
ic
m
em
br
an
e
tr
an
sp
la
nt
at
io
n
in
ac
ut
e
TE
N
Fi
rs
t
us
e
of
am
ni
ot
ic
m
em
br
an
e
on
ex
te
rn
al
ey
el
id
an
d
lid
m
ar
gi
n
Fi
rs
t
to
de
m
on
st
ra
te
of
ef
fe
ct
iv
en
es
s
of
A
M
T
in
pr
ev
en
tin
g
lid
/c
or
ne
a
ad
he
sio
n
an
d
re
st
or
in
g
oc
ul
ar
su
rfa
ce
in
te
gr
ity
Ko
ba
ya
sh
ie
t
al
[2
3]
20
06
In
te
rv
en
tio
na
l
C
as
e
Re
po
rt
TE
N
Se
ve
re
6
1
Fi
rs
tt
o
sh
ow
ev
id
en
ce
th
at
re
pe
at
AM
T
is
ef
fe
ct
iv
e
in
tre
at
in
g
pe
rs
ist
en
t
ep
ith
el
ia
ld
ef
ec
ts
af
te
ri
ni
tia
le
ar
ly
AM
T
A
tz
or
ie
t
al
[2
4]
20
06
In
te
rv
en
tio
na
l
C
as
e
Re
po
rt
TE
N
Se
ve
re
68
1
Fi
rs
tr
ep
or
tt
o
id
en
tif
y
an
an
gi
ot
en
sin
II
re
ce
pt
or
an
ta
go
ni
st
as
a
po
ss
ib
le
ca
us
at
iv
e
ag
en
t
Ta
nd
on
et
al
[2
5]
20
07
In
te
rv
en
tio
na
l
C
as
e
Re
po
rt
TE
N
Se
ve
re
12
1
U
se
s
re
pe
at
ed
ep
ila
tio
n
to
pr
ev
en
t
co
rn
ea
le
pi
th
el
io
pa
th
y
in
ac
ut
e
an
d
ch
ro
ni
c
st
ag
es
Sh
am
m
as
et
al
[2
1]
20
09
Re
tr
os
pe
ct
iv
e
C
as
e
Se
rie
s
SJ
S
or
TE
N
Se
ve
re
2
–
82
8
Fi
rs
t
to
co
m
pa
re
Pr
ok
er
a
us
e
(p
ar
tia
lc
ov
er
ag
e
of
oc
ul
ar
su
rfa
ce
)
an
d
A
M
T
us
e
(c
om
pl
et
e
co
ve
ra
ge
)
G
re
go
ry
[1
9]
20
11
Pr
os
pe
ct
iv
e
C
as
e
Se
rie
s
SJ
S
or
TE
N
Se
ve
re
3
–
28
10
A
ll
pa
tie
nt
s
tr
ea
te
d
w
ith
in
10
da
ys
of
di
se
as
e
on
se
t
Re
pe
at
A
M
T
pe
rfo
rm
ed
ev
er
y
10
-1
4
da
ys
if
oc
ul
ar
su
rfa
ce
in
fla
m
m
at
io
n
pe
rs
ist
ed
Fu
rt
he
r
ev
id
en
ce
to
sh
ow
th
at
Pr
ok
er
a
al
on
e
w
as
in
ad
eq
ua
te
H
su
et
al
[2
0]
20
12
C
as
e
C
on
tr
ol
St
ud
y
SJ
S
or
TE
N
M
ild
-S
ev
er
e
N
/A
30
(1
3
tre
at
ed
w
ith
A
M
T,
17
m
ed
ic
al
m
an
ag
em
en
ta
lo
ne
)
Sh
ow
ed
be
tt
er
vi
su
al
ou
tc
om
es
in
A
M
T
tr
ea
te
d
ey
es
ov
er
ey
es
w
ith
ou
t
A
M
T
ac
ro
ss
th
e
sp
ec
tr
um
of
di
se
as
e
Sh
ow
ed
su
pe
rio
r
ou
tc
om
es
in
ey
es
w
ith
A
M
T
do
ne
w
ith
in
th
e
fir
st
w
ee
k
of
di
se
as
e
on
se
t
Ki
m
et
al
[2
6]
20
14
Re
tr
os
pe
ct
iv
e
C
as
e
Se
rie
s
SJ
S
or
TE
N
M
ild
-S
ev
er
e
1
–
59
51
D
em
on
st
ra
te
d
th
at
pa
tie
nt
s<
18
ye
ar
s
of
ag
e
ha
d
w
or
se
oc
ul
ar
ou
tc
om
es
D
em
on
st
ra
te
d
be
ne
fit
s
of
IV
IG
+
st
er
oi
d
us
e
on
oc
ul
ar
ou
tc
om
es
Lo
pe
z-
G
ar
ci
a
et
al
[2
7]
20
14
Pr
os
pe
ct
iv
e
C
as
e
Se
rie
s
TE
N
M
od
er
at
e
-S
ev
er
e
N
/A
5
Fi
rs
tt
o
sh
ow
hi
st
ol
og
ic
al
ev
id
en
ce
to
su
pp
or
tb
en
ef
ic
ia
le
ffe
ct
s
of
A
M
T
Sh
ar
m
a
et
al
[2
8]
20
16
Ra
nd
om
iz
ed
Co
nt
ro
lle
d
Tr
ia
l
SJ
S
N
/A
(p
ro
sp
ec
tiv
e)
31
.7
±
16
.7
27
.9
±
12
.5
25
+
25
O
nl
y
pr
os
pe
ct
iv
e
ra
nd
om
iz
ed
co
nt
ro
lt
ria
le
va
lu
at
in
g
th
e
ef
fic
ac
y
of
A
M
T
in
th
e
m
an
ag
em
en
t
of
ac
ut
e
SJ
S.
G
re
go
ry
[2
9]
20
16
Pr
os
pe
ct
iv
e
C
as
e
Se
rie
s
SJ
S
&
TE
N
A
ll
se
ve
rit
y
N
/A
79
Pr
op
os
ed
a
gr
ad
in
g
sy
st
em
to
fa
ci
lit
at
e
de
ci
si
on
m
ak
in
g
on
w
he
n
to
do
A
M
T
Chow et al. BMC Ophthalmology  (2017) 17:65 Page 5 of 7
had their initial ophthalmic assessment performed in the
initial referring center and no further ophthalmic assess-
ment record was available after being transferred to our
institution. It was important for us to exclude these
cases to avoid misclassifying them as ‘acute stage disease’,
since some of these cases might already have many days
to weeks of ocular manifestations prior to admission to
our burn ICU. Moreover, our center did not adopt using
the SCORTEN score until the recent few years. As a re-
sult, majority of our retrospective cases did not have the
SCORTEN value and we could not perform correlation
analysis between the SCORTEN value and the severity
of acute ocular involvement. However, it has been re-
cently shown that the SCORTEN value did not correlate
with the severity of eye involvement in the acute setting
[7]. The lack of a unified categorization method is an-
other major limitation when studying this disease entity.
As explained above, we could only group all cases with
<30% body surface involvement into a single “SJS or SJS/
TEN overlap” group instead of two. Lastly, studies have
shown that the severity of involvement in the acute
phase did not predict the late ocular outcome [15],
and this current study only focused on the acute
phase of the disease. However, given the low inci-
dence of the disease, we believe our study would be
an important addition to the current literature, espe-
cially on Chinese patients.
Conclusion
Ocular involvement is common during the acute phase
in both SJS (40%) and TEN patients (75%) in our series
of Chinese patients. TEN patients were more likely to
have acute ocular surface inflammation than SJS pa-
tients, but the difference was mainly in the mild involve-
ment group. The routine use of early intravenous pulse
steroid in all our cases could have explained our low in-
cidence of moderate and severe ocular involvement.
Whether the acute ocular manifestation predicts late
ocular complications, or whether there would be differ-
ence in the chronic ocular manifestations between the
SJS or TEN was not explored in this current study.
These issues could be further explored in a multicenter
prospective study comparing acute ocular manifesta-
tions, response to treatment and visual outcomes in SJS
and TEN patients, that is currently underway by our in-
vestigative team.
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